---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-019258"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2023-05-26T23:59:59+00:00"
generated_at: "2026-06-14T13:09:53.200271+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics receives Nasdaq deficiency notice for late Q1 10-Q filing

## Summary
- Received Nasdaq deficiency on May 23, 2023 for not filing Q1 10-Q on time.
- Failure due to recent auditor change from Plante & Moran to Moss Adams.
- Company has until July 22, 2023 to submit a plan to regain compliance.
- If plan accepted, Nasdaq may grant exception until November 20, 2023.
- Company expects to file Q1 10-Q in coming weeks to resolve delinquency.

## SEC filing metadata
- accession: 0001493152-23-019258
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2023-05-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315223019258/0001493152-23-019258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315223019258/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-019258
- JSON: https://secwatch.observer/filing/0001493152-23-019258.json
- Plain text: https://secwatch.observer/filing/0001493152-23-019258.txt

## Key facts
- Listing & Compliance Notices
  Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: May 23, 2023, Vivos Therapeutics, Inc. (the “ Company ”) received a staff deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) indicating that, because Nasdaq has not yet received the Company’s Form 10-Q for the quarter ended March 31, 2023, the Company no longer complies with the Nasdaq Listing Rules for continued listing under Rule 5250(c)(1) (the “ Periodic Filing Requirement ”). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. The Company’s failure to file its Form 10-Q for the quarter ended March 31, 2023 is consider
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315223019258/0001493152-23-019258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.